Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct;4(4):705-710.
doi: 10.3892/ol.2012.785. Epub 2012 Jul 4.

KRAS mutations and subtyping in colorectal cancer in Jordanian patients

Wafa M Elbjeirami  1 , Maher A Sughayer
Affiliations

KRAS mutations and subtyping in colorectal cancer in Jordanian patients

Wafa M Elbjeirami et al. Oncol Lett. 2012 Oct.

Abstract

Colorectal cancer (CRC) is one of the most common malignancies in the Western world and Jordan. v-Ki-ras2 Kirsten rat sarcoma (KRAS) mutations represent an early event in the development and progression of CRC. Previous studies have demonstrated that KRAS mutations serve as a predictor of response to EGFR-targeted therapies for patients with metastatic CRC. The aim of this study was to determine the portion of CRC patients with wildtype KRAS status and molecular subtypes of KRAS mutations in Jordan as compared with other countries. DNA was isolated from 100 consecutive colorectal carcinoma specimens from patients who underwent surgical resection or colonoscopic biopsies of colorectal tumors and had developed metastatic disease. KRAS mutations were detected by hybridization-based strip assay as well as RT-PCR-based assay and confirmed by standard Sanger sequencing of codon 12 and 13 of exon 1 of the KRAS gene. Among 100 tested patients, 56% had a wt-KRAS genotype and 44% had a mutated KRAS genotype. The pGly12Asp was the most commonly detected mutation (54.5%). KRAS mutations were independently associated with patient age, gender and tumoral variables. The ratio of mutated versus wt-KRAS patients in this study is similar to those reported in Western countries but contrasts to neighboring Middle Eastern countries. Colorectal carcinoma cases from Jordan had higher KRAS mutation frequencies compared with other Middle Eastern countries which is likely to reflect different molecular pathogenesis and environmental exposures.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Frequency of KRAS mutations among Jordanian CRC patients. KRAS, v-Ki-ras2 Kirsten rat sarcoma.
Figure 2.
Figure 2.
Mutational events in KRAS gene. KRAS codons 12 and 13 analysis in 100 patients. KRAS, v-Ki-ras2 Kirsten rat sarcoma.
Figure 3.
Figure 3.
Distribution chart of tested KRAS mutations in the group of tested patients. The CRCs of Jordanian patients had more transitional mutations as compared with transversion mutations. KRAS, v-Ki-ras2 Kirsten rat sarcoma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. - PubMed
    1. Tarawneh M, Nimri O, Arkoob K, Al Zhagal M. Cancer Incidence in Jordan annual report, 2009
    1. Penna C, Nordlinger B. Colorectal metastasis (liver and lung) Surg Clin North Am. 2002;82:1075–1090. - PubMed
    1. Van Krieken JH, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 2008;453:417–431. - PubMed
    1. Fransėn K, Klintenäs M, Osterström A, et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis. 2004;25:527–533. - PubMed